Skip to main content
Fig. 29 | Cancer Nanotechnology

Fig. 29

From: RETRACTED ARTICLE: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation

Fig. 29

Expression of Bax, BCL-2, cleaved PARP, and cleaved Caspase 3 was observed by ELISA in the PC group compared to pure VC and NFs of VC-loaded TCs-HA treatment groups (n = 10, mean ± SD, p ≤ 0.05, *** highly significant)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us